Skip to main content
Erschienen in: International Cancer Conference Journal 4/2020

08.07.2020 | Case report

Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review

verfasst von: Toshihiko Masago, Susumu Kobayakawa, Yuu Ohtani, Kenjirou Taniguchi, Takuji Naka, Naoto Kuroda, Chihiro Takahashi, Tadahiro Isoyama, Takehiro Sejima

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

A 68-year-old man was followed up with chronic kidney disease. Follow-up CT incidentally detected a tumor at the left kidney and multiple small nodular shadows in the lungs bilaterally. The patient underwent needle biopsy and was diagnosed with Xp11.2 translocation renal cell carcinoma (RCC) pathologically. Hence, laparoscopic nephrectomy was performed. Fluorescence in situ hybridization analysis revealed a break-apart of the transcription factor E3 (TFE3) genes in the left tumor. After 2 months postoperatively, nivolumab and ipilimumab were administered thrice intravenously, considering the intermediate risk by the IMDC risk classification. However, pleural effusion occurred but was removed adequately. Lung metastasis decreased, but new metastasis occurred at the left iliopsoas muscle. Target therapy was performed with axitinib. Unfortunately, he died 6 months later postoperatively. These tumors commonly occur in children than in adults, and very rare in elderly patients. Xp11.2 translocation RCC in the elderly has a poorer prognosis than that in children. To date, no effective treatment for Xp11.2 translocation RCC has been established.
Literatur
1.
Zurück zum Zitat Macher-Goeppinger S, Roth W, Wagener N et al (2012) Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 25:308–315CrossRef Macher-Goeppinger S, Roth W, Wagener N et al (2012) Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 25:308–315CrossRef
2.
Zurück zum Zitat Srigley JR, Delahunt B, Eble JN et al (2013) The international society of urological pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489CrossRef Srigley JR, Delahunt B, Eble JN et al (2013) The international society of urological pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489CrossRef
3.
Zurück zum Zitat Argani P, Olgac S, Tickoo SK et al (2007) Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 8:1149–1160CrossRef Argani P, Olgac S, Tickoo SK et al (2007) Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 8:1149–1160CrossRef
4.
Zurück zum Zitat Sidhar S (1996) The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 5:1333–1338CrossRef Sidhar S (1996) The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 5:1333–1338CrossRef
5.
Zurück zum Zitat Mathur M, Das S, Samuels HH (2003) PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequesteration. Oncogene 22:5031–5044CrossRef Mathur M, Das S, Samuels HH (2003) PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequesteration. Oncogene 22:5031–5044CrossRef
6.
Zurück zum Zitat Clark J, Lu YJ, Sidhar SK et al (1997) Fusion of splicing factor genes PSF and NonO(p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15:2233–2239CrossRef Clark J, Lu YJ, Sidhar SK et al (1997) Fusion of splicing factor genes PSF and NonO(p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15:2233–2239CrossRef
7.
Zurück zum Zitat Argani P, Lui MY, Couyruier J et al (2003) A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22:5374–5378CrossRef Argani P, Lui MY, Couyruier J et al (2003) A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22:5374–5378CrossRef
8.
Zurück zum Zitat Bruder E, Passera O, Harms D et al (2004) Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pahol 28:1117–1132CrossRef Bruder E, Passera O, Harms D et al (2004) Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pahol 28:1117–1132CrossRef
9.
Zurück zum Zitat Chan TY (2005) World Health Organization classification of tumours: pathology and genetics tumours of the urinary system and male genital organs. Urology 65:214–215CrossRef Chan TY (2005) World Health Organization classification of tumours: pathology and genetics tumours of the urinary system and male genital organs. Urology 65:214–215CrossRef
10.
Zurück zum Zitat Franzini A, Picozzi SCM, Politi PJ et al (2007) A case of renal cancer with TFE3 gene fusion in an elderly man. Clinical, radiological and surgical findings. Urol Int 78:179–181CrossRef Franzini A, Picozzi SCM, Politi PJ et al (2007) A case of renal cancer with TFE3 gene fusion in an elderly man. Clinical, radiological and surgical findings. Urol Int 78:179–181CrossRef
11.
Zurück zum Zitat Iinuma K, Kojima K, Okamoto K et al (2016) A case of Xp.11.2 translocation renal cell carcinoma diagnosed by fluorescence in situ hybridization (FISH). Hinyokiyo 62:411–414 Iinuma K, Kojima K, Okamoto K et al (2016) A case of Xp.11.2 translocation renal cell carcinoma diagnosed by fluorescence in situ hybridization (FISH). Hinyokiyo 62:411–414
12.
Zurück zum Zitat Pan X, Quan J, Zhao L et al (2017) Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: a case report. Mol Clin Oncol 8:83–85PubMedPubMedCentral Pan X, Quan J, Zhao L et al (2017) Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: a case report. Mol Clin Oncol 8:83–85PubMedPubMedCentral
13.
Zurück zum Zitat Karashima T, Kuno T, Kuroda N et al (2018) Bilateral Xp 11.2 translocation renal cell carcinoma: a case report. BMC Urol 18:106–111CrossRef Karashima T, Kuno T, Kuroda N et al (2018) Bilateral Xp 11.2 translocation renal cell carcinoma: a case report. BMC Urol 18:106–111CrossRef
14.
Zurück zum Zitat Martignoni G, Gobbo S, Camparo P et al (2011) Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 24:1313–1319CrossRef Martignoni G, Gobbo S, Camparo P et al (2011) Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 24:1313–1319CrossRef
15.
Zurück zum Zitat Gao X, McDermott DF (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Bio Ther 18:947–957CrossRef Gao X, McDermott DF (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Bio Ther 18:947–957CrossRef
16.
Metadaten
Titel
Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review
verfasst von
Toshihiko Masago
Susumu Kobayakawa
Yuu Ohtani
Kenjirou Taniguchi
Takuji Naka
Naoto Kuroda
Chihiro Takahashi
Tadahiro Isoyama
Takehiro Sejima
Publikationsdatum
08.07.2020
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2020
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-020-00430-6

Weitere Artikel der Ausgabe 4/2020

International Cancer Conference Journal 4/2020 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.